Bevacizumab in hereditary hemorrhagic telangiectasia.

To the Editor: Hereditary hemorrhagic telangiectasia (HHT) (also known as the Osler–Weber–Rendu syndrome) is an inherited vascular dysplasia whose main features are mucocutaneous telangiectasias, epistaxis, gastrointestinal bleeding, and iron-deficiency anemia.1 It is a disorder of unbalanced angiogenesis.2 Patients have elevated plasma concentrations and tissue expression of vascular endothelial growth factor (VEGF) and transforming growth factor β (TGF-β).3 TGF-β stimulates the production of VEGF, which plays a key role in angiogenesis. We report on a patient with HHT1 who had an impressive response to an anti-VEGF antibody, bevacizumab. A 42-year-old man presented with long-standing epistaxis, hemoptysis, and a hemoglobin level of . . .